Repurposing of statins via inhalation to treat lung inflammatory conditions

Lim, 2013, Role of statins in coronary artery disease, Chonnam Med. J., 49, 1, 10.4068/cmj.2013.49.1.1 Robinson, 2005, Pleiotropic effects of statins: benefit beyond cholesterol reduction?: a meta-regression analysis, J. Am. Coll. Cardiol., 46, 1855, 10.1016/j.jacc.2005.05.085 Liao, 2005, Pleiotropic effects of statins, Annu. Rev. Pharmacol. Toxicol., 45, 89, 10.1146/annurev.pharmtox.45.120403.095748 Young, 2009, Pharmacological actions of statins: potential utility in COPD, Eur. Respir. Rev., 18, 222, 10.1183/09059180.00005309 Tulbah, 2016, Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons, Expert Opin. Drug Deliv., 13, 1407, 10.1080/17425247.2016.1193150 Yuan, 2012, Statins as potential therapeutic drug for asthma?, Respir. Res., 13, 108, 10.1186/1465-9921-13-108 Walsh, 2008, Statins as emerging treatments for asthma and chronic obstructive pulmonary disease, Expert Rev. Respir. Med., 2, 329, 10.1586/17476348.2.3.329 Athanazio, 2012, Airway disease: similarities and differences between asthma, COPD and bronchiectasis, Clinics, 67, 1335, 10.6061/clinics/2012(11)19 Organization, W.H. WHO Marin, 2011, Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management, Expert Opin. Drug Deliv., 8, 1205, 10.1517/17425247.2011.588697 O'Connor, 1992, Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma, N. Engl. J. Med., 327, 1204, 10.1056/NEJM199210223271704 Barnes, 2009, Glucocorticoid resistance in inflammatory diseases, Lancet, 373, 1905, 10.1016/S0140-6736(09)60326-3 Istvan, 2001, Structural mechanism for statin inhibition of HMG-CoA reductase, Science, 292, 1160, 10.1126/science.1059344 Hentschel, 2016, Protein lipid modifications—more than just a greasy ballast, Proteomics, 16, 759, 10.1002/pmic.201500353 Palsuledesai, 2015, Protein prenylation: enzymes, therapeutics, and biotechnology applications, ACS Chem. Biol., 10, 51, 10.1021/cb500791f Yeganeh, 2014, Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease, Pharmacol. Ther., 143, 87, 10.1016/j.pharmthera.2014.02.007 Zhang, 1996, Protein prenylation: molecular mechanisms and functional consequences, Annu. Rev. Biochem., 65, 241, 10.1146/annurev.bi.65.070196.001325 Bu, 2011, Mechanisms for the anti-inflammatory effects of statins, Curr. Opin. Lipidol., 22, 165, 10.1097/MOL.0b013e3283453e41 Jain, 2005, Anti-inflammatory effects of statins: clinical evidence and basic mechanisms, Nat. Rev. Drug Discov., 4, 977, 10.1038/nrd1901 Zhu, 2012, New roles of HDL in inflammation and hematopoiesis, Annu. Rev. Nutr., 32, 161, 10.1146/annurev-nutr-071811-150709 Hughes, 2007, A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo, Calcif. Tissue Int., 81, 403, 10.1007/s00223-007-9078-1 Le, 2014, Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents, J. Immunol., 193, 3803, 10.4049/jimmunol.1400571 Niesor, 2015, Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein, Cardiovasc. Drugs Ther., 29, 7, 10.1007/s10557-015-6570-0 Sen-Banerjee, 2005, Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells, Circulation, 112, 720, 10.1161/CIRCULATIONAHA.104.525774 Zhou, 2010, Pleiotropic effects of statins; basic research and clinical perspectives, Circ. J., 74, 818, 10.1253/circj.CJ-10-0110 Kiener, 2001, Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors, Int. Immunopharmacol., 1, 105, 10.1016/S0162-3109(00)00272-1 Knapp, 2000, Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death, Atherosclerosis, 152, 217, 10.1016/S0021-9150(99)00462-1 Roberts, 2008, Rho family GTPase modification and dependence on CAAX motif-signaled posttranslational modification, J. Biol. Chem., 283, 25150, 10.1074/jbc.M800882200 Chu, 2015, Endothelial protective genes induced by statin are mimicked by ERK5 activation as triggered by a drug combination of FTI-277 and GGTI-298, Biochim. Biophys. Acta, 1850, 1415, 10.1016/j.bbagen.2015.03.011 Kou, 2009, Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta, J. Biol. Chem., 284, 14734, 10.1074/jbc.M808664200 Cordle, 2005, Mechanisms of statin-mediated inhibition of small G-protein function, J. Biol. Chem., 280, 34202, 10.1074/jbc.M505268200 Wu, 2013, Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation, Biochem. Pharmacol., 85, 1753, 10.1016/j.bcp.2013.04.009 Ness, 1994, Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by sterols and nonsterols in rat liver, Arch. Biochem. Biophys., 308, 420, 10.1006/abbi.1994.1059 Ando, 2004, Effects of pravastatin on the expression of ATP-binding cassette transporter A1, J. Pharmacol. Exp. Ther., 311, 420, 10.1124/jpet.104.068213 Schonewille, 2016, Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice, J. Lipid Res., 57, 1455, 10.1194/jlr.M067488 Bilheimer, 1983, Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes, Proc. Natl. Acad. Sci. U. S. A., 80, 4124, 10.1073/pnas.80.13.4124 Ness, 1996, Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation, Arch. Biochem. Biophys., 325, 242, 10.1006/abbi.1996.0030 Chai, 2017, Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation, Respir. Res., 18, 41, 10.1186/s12931-017-0526-9 Oram, 2001, ABCA1. The gatekeeper for eliminating excess tissue cholesterol, J. Lipid Res., 42, 1173, 10.1016/S0022-2275(20)31566-2 Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc. Natl. Acad. Sci. U. S. A., 101, 9774, 10.1073/pnas.0403506101 Baldan, 2006, Deletion of the transmembrane transporter ABCG1 results in progressive pulmonary lipidosis, J. Biol. Chem., 281, 29401, 10.1074/jbc.M606597200 Bates, 2005, Pulmonary abnormalities due to ABCA1 deficiency in mice, Am. J. Phys. Lung Cell. Mol. Phys., 289, L980 Rigamonti, 2008, Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men, Arterioscler. Thromb. Vasc. Biol., 28, 1050, 10.1161/ATVBAHA.107.158998 Wong, 2004, Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux, Arterioscler. Thromb. Vasc. Biol., 24, 2365, 10.1161/01.ATV.0000148707.93054.7d Wong, 2006, SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR, Biochem. J., 400, 485, 10.1042/BJ20060914 Habib, 2007, Modulation of COX-2 expression by statins in human monocytic cells, FASEB J., 21, 1665, 10.1096/fj.06-6766com Goldstein, 2006, Protein sensors for membrane sterols, Cell, 124, 35, 10.1016/j.cell.2005.12.022 Marquart, 2010, miR-33 links SREBP-2 induction to repression of sterol transporters, Proc. Natl. Acad. Sci. U. S. A., 107, 12228, 10.1073/pnas.1005191107 Horie, 2010, MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo, Proc. Natl. Acad. Sci. U. S. A., 107, 17321, 10.1073/pnas.1008499107 Rayner, 2010, MiR-33 contributes to the regulation of cholesterol homeostasis, Science, 328, 1570, 10.1126/science.1189862 Sone, 2004, Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages, Biochem. Biophys. Res. Commun., 316, 790, 10.1016/j.bbrc.2004.02.121 Argmann, 2005, Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux, J. Biol. Chem., 280, 22212, 10.1074/jbc.M502761200 Yano, 2007, Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages, Circ. Res., 100, 1442, 10.1161/01.RES.0000268411.49545.9c Bochem, 2015, Increased systemic and plaque inflammation in ABCA1 mutation carriers with attenuation by statins, Arterioscler. Thromb. Vasc. Biol., 35, 1663, 10.1161/ATVBAHA.114.304959 Ma, 2012, ABCA1 protein enhances Toll-like receptor 4 (TLR4)-stimulated interleukin-10 (IL-10) secretion through protein kinase A (PKA) activation, J. Biol. Chem., 287, 40502, 10.1074/jbc.M112.413245 Yvan-Charvet, 2008, Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions, Circulation, 118, 1837, 10.1161/CIRCULATIONAHA.108.793869 Zhu, 2008, Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages, J. Biol. Chem., 283, 22930, 10.1074/jbc.M801408200 Li, 2005, Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis, J. Biol. Chem., 280, 21763, 10.1074/jbc.M501759200 Baldan, 2008, Loss of ABCG1 results in chronic pulmonary inflammation, J. Immunol., 180, 3560, 10.4049/jimmunol.180.5.3560 Coso, 1995, The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway, Cell, 81, 1137, 10.1016/S0092-8674(05)80018-2 Dichtl, 2003, HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol., 23, 58, 10.1161/01.ATV.0000043456.48735.20 Langert, 2013, Cdc42 GTPases facilitate TNF-alpha-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells, J. Peripher. Nerv. Syst., 18, 199, 10.1111/jns5.12032 Lai, 2012, Interleukin-8 induces the endothelial cell migration through the Rac 1/RhoA-p38MAPK pathway, Eur. Rev. Med. Pharmacol. Sci., 16, 630 Lin, 2015, Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-kappaB pathways in human lung epithelial cells, Eur. J. Pharmacol., 767, 135, 10.1016/j.ejphar.2015.10.018 Tsubaki, 2016, Statins inhibited the MIP-1alpha expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells, Biomed Pharmacother, 78, 23, 10.1016/j.biopha.2015.12.017 Williams, 2008, Rac mediates TNF-induced cytokine production via modulation of NF-kappaB, Mol. Immunol., 45, 2446, 10.1016/j.molimm.2007.12.011 Jin, 2013, Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages, PLoS One, 8, 10.1371/journal.pone.0073706 Antoniades, 2010, Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity, Circulation, 122, S66, 10.1161/CIRCULATIONAHA.109.927376 Nakagami, 2003, A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms, Ann. Med., 35, 398, 10.1080/07853890310001294 Wilkinson, 2018, Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells, J. Cell. Physiol., 233, 186, 10.1002/jcp.26064 Nishimoto, 2006, MAPK signalling: ERK5 versus ERK1/2, EMBO Rep., 7, 782, 10.1038/sj.embor.7400755 Pearson, 2001, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr. Rev., 22, 153 Lee, 1995, Primary structure of BMK1: a new mammalian map kinase, Biochem. Biophys. Res. Commun., 213, 715, 10.1006/bbrc.1995.2189 Zhou, 1995, Components of a new human protein kinase signal transduction pathway, J. Biol. Chem., 270, 12665, 10.1074/jbc.270.21.12665 Ohnesorge, 2010, Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4), J. Biol. Chem., 285, 26199, 10.1074/jbc.M110.103127 Parmar, 2006, Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2, J. Clin. Invest., 116, 49, 10.1172/JCI24787 Akaike, 2004, Mol. Cell. Biol., 24, 8691, 10.1128/MCB.24.19.8691-8704.2004 Kasler, 2000, ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain, Mol. Cell. Biol., 20, 8382, 10.1128/MCB.20.22.8382-8389.2000 Woo, 2008, Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells, Circ. Res., 102, 538, 10.1161/CIRCRESAHA.107.156877 Kumar, 2005, Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases, Mol. Cell. Biol., 25, 5893, 10.1128/MCB.25.14.5893-5903.2005 Macnee, 2001, Oxidative stress and lung inflammation in airways disease, Eur. J. Pharmacol., 429, 195, 10.1016/S0014-2999(01)01320-6 Rahman, 1998, Role of transcription factors in inflammatory lung diseases, Thorax, 53, 601, 10.1136/thx.53.7.601 Meyer, 2015, Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants, Am. J. Phys. Lung Cell. Mol. Phys., 308, L1189 Ingram, 2016, Role of matrix metalloproteinases-1 and -2 in interleukin-13–suppressed elastin in airway fibroblasts in asthma, Am. J. Respir. Cell Mol. Biol., 54, 41, 10.1165/rcmb.2014-0290OC Lora, 2005, Tumor necrosis factor-α triggers mucus production in airway epithelium through an IκB kinase β-dependent mechanism, J. Biol. Chem., 280, 36510, 10.1074/jbc.M507977200 Ou, 2008, Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats, Chin. Med. J. (Engl.), 121, 1680, 10.1097/00029330-200809010-00018 McKay, 2004, A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma, J. Immunol., 172, 2903, 10.4049/jimmunol.172.5.2903 Yeh, 2004, Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation, J. Biomed. Sci., 11, 599, 10.1007/BF02256124 Huang, 2003, HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages, J. Biomed. Sci., 10, 396, 10.1007/BF02256431 Zeki, 2009, Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond, Am. J. Respir. Crit. Care Med., 180, 731, 10.1164/rccm.200901-0018OC Zeki, 2012, Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells, Respir. Res., 13, 38, 10.1186/1465-9921-13-38 Davis, 2013, Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy, Eur. Respir. J., 42, 350, 10.1183/09031936.00042512 Liu, 2014, Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?, Exp. Mol. Med., 46, e113, 10.1038/emm.2014.55 Chiba, 2010, RhoA, a possible target for treatment of airway hyperresponsiveness in bronchial asthma, J. Pharmacol. Sci., 114, 239, 10.1254/jphs.10R03CR Kume, 2008, RhoA/Rho-kinase as a therapeutic target in asthma, Curr. Med. Chem., 15, 2876, 10.2174/092986708786242831 Lee, 2005, Simvastatin inhibits cigarette smoking–induced emphysema and pulmonary hypertension in rat lungs, Am. J. Respir. Crit. Care Med., 172, 987, 10.1164/rccm.200501-041OC Turner, 2005, Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels, FASEB J., 19, 804, 10.1096/fj.04-2852fje Chen, 2010, Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway, Int. Immunopharmacol., 10, 685, 10.1016/j.intimp.2010.03.012 Liou, 2014, Oral lovastatin attenuates airway inflammation and mucus secretion in ovalbumin-induced murine model of asthma, Allergy, Asthma Immunol. Res., 6, 548, 10.4168/aair.2014.6.6.548 Marin, 2013, Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies, Eur. J. Pharm. Biopharm., 84, 566, 10.1016/j.ejpb.2013.01.021 Tulbah, 2016, Biological effects of simvastatin formulated as pMDI on pulmonary epithelial cells, Pharm. Res., 33, 92, 10.1007/s11095-015-1766-3 Tulbah, 2015, Dry powder formulation of simvastatin, Expert Opin. Drug Deliv., 12, 857, 10.1517/17425247.2015.963054 Tulbah, 2017, Inhaled simvastatin nanoparticles for inflammatory lung disease, Nanomedicine (London), 12, 2471, 10.2217/nnm-2017-0188 Zeki, 2010, Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?, Transl. Res., 156, 335, 10.1016/j.trsl.2010.09.003 Bhattacharjee, 2015, Statins in asthma: potential beneficial effects and limitations, BMC Pulm. Med., 2015 Golomb, 2008, Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism, Am. J. Cardiovasc. Drugs, 8, 373, 10.2165/0129784-200808060-00004 Maji, 2013, Safety of statins, Indian J. Endocrinol. Metab., 17, 636, 10.4103/2230-8210.113754 Stancu, 2001, Statins: mechanism of action and effects, J. Cell. Mol. Med., 5, 378, 10.1111/j.1582-4934.2001.tb00172.x Prueksaritanont, 1997, In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s, Drug Metab. Dispos., 25, 1191 Serajuddin, 1991, Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-COA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin, J. Pharm. Sci., 80, 830, 10.1002/jps.2600800905 Hamelin, 1998, Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors, Trends Pharmacol. Sci., 19, 26, 10.1016/S0165-6147(97)01147-4 Munger, 1991, A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases, J. Biol. Chem., 266, 18832, 10.1016/S0021-9258(18)55139-5 Anttila, 1997, Expression and localization of CYP3A4 and CYP3A5 in human lung, Am. J. Respir. Cell Mol. Biol., 16, 242, 10.1165/ajrcmb.16.3.9070608 Takahashi, 2008, Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice, Am. J. Phys. Lung Cell. Mol. Phys., 294, L882 Müller, 2010, Simvastatin attenuates ventilator-induced lung injury in mice, Crit. Care, 14, R143, 10.1186/cc9209 Tschernig, 2010, Controversial data on simvastatin in asthma: what about the rat model?, J. Asthma Allergy, 3, 57, 10.2147/JAA.S10810 Xu, 2012, Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma, Int. Immunopharmacol., 12, 556, 10.1016/j.intimp.2012.01.012 Elbadawi-Sidhu, 2017, The fate of inhaled simvastatin in the lungs and systemic circulation, Am. J. Respir. Crit. Care Med., 195, A6459 Basu, 2013, Intranasal delivery of simvastatin: improved effects over systemic delivery to suppress allergic airway inflammation and hyperreactivity, Am. J. Respir. Crit. Care Med., 187, A4011 Basu, 2014, Inhibition of airway inflammation and hyperreactivity by inhaled simvastatin, Am. J. Respir. Crit. Care Med., 189, A2690 Ryu, 2016, Inhaled simvastatin concomitantly prevents generation of oxidized phosphatidylcholine, airway inflammation, and hyperresponsiveness in allergen-challenged mice, Am. J. Respir. Crit. Care Med., 193, A1263 Tulbah, 2014, Novel simvastatin inhalation formulation and characterisation, AAPS PharmSciTech, 15, 956, 10.1208/s12249-014-0127-6 Haghi, 2014, Across the pulmonary epithelial barrier: integration of physicochemical properties and human cell models to study pulmonary drug formulations, Pharmacol. Ther., 144, 235, 10.1016/j.pharmthera.2014.05.003 Ong, 2014, In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation, Eur. J. Pharm. Biopharm., 86, 83, 10.1016/j.ejpb.2013.06.024 Tronde, 2003, Drug absorption from the isolated perfused rat lung–correlations with drug physicochemical properties and epithelial permeability, J. Drug Target., 11, 61, 10.1080/1061186031000086117 Ong, 2013, Pharmaceutical applications of the Calu-3 lung epithelia cell line, Expert Opin. Drug Deliv., 10, 1287, 10.1517/17425247.2013.805743 Zeki, 2015, Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins, Phys. Rep., 3 Roth, 2012, OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies, Br. J. Pharmacol., 165, 1260, 10.1111/j.1476-5381.2011.01724.x Kalliokoski, 2009, Impact of OATP transporters on pharmacokinetics, Br. J. Pharmacol., 158, 693, 10.1111/j.1476-5381.2009.00430.x Bosquillon, 2010, Drug transporters in the lung—do they play a role in the biopharmaceutics of inhaled drugs?, J. Pharm. Sci., 99, 2240, 10.1002/jps.21995 Nickel, 2016, Transport mechanisms at the pulmonary mucosa: implications for drug delivery, Expert Opin. Drug Deliv., 13, 667, 10.1517/17425247.2016.1140144 Luvai, 2012, Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease, Clin. Med. Insights Cardiol., 6, 10.4137/CMC.S4324 Brown, 2001, Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C, Atheroscler. Suppl., 2, 90, 10.1016/S1567-5688(01)80225-7 Mctaggart, 2001, Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor1, Am. J. Cardiol., 87, 28, 10.1016/S0002-9149(01)01454-0 Patil-Gadhe, 2016, Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: optimization by factorial design, Int. J. Pharm., 501, 199, 10.1016/j.ijpharm.2016.01.080 Catapano, 2012, Pitavastatin: a different pharmacological profile, J. Clin. Lipidol., 7, 3, 10.2217/clp.12.21 Alagona, 2010, Pitavastatin: evidence for its place in treatment of hypercholesterolemia, Core Evid., 5, 91, 10.2147/CE.S8008 Ose, 2011, Pitavastatin: finding its place in therapy, Ther. Adv. Chronic Dis., 2, 101, 10.1177/2040622310389227 Kubo, 2009, Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium, Arterioscler. Thromb. Vasc. Biol., 29, 796, 10.1161/ATVBAHA.108.182584 Oda, 2010, Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia, J. Vasc. Surg., 52, 412, 10.1016/j.jvs.2010.03.020 Chen, 2011, Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension, Hypertension, 57, 343, 10.1161/HYPERTENSIONAHA.110.157032 Parashar, 2016, Design & development of novel lipid based carrier system for delivery of pitavastatin calcium, Int. J. Pharm. Sci. Res., 7, 5030 EPA, U Niemi, 2010, Transporter pharmacogenetics and statin toxicity, Clin. Pharmacol. Ther., 87, 130, 10.1038/clpt.2009.197 Fujino, 2005, Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase, J. Pharm. Pharmacol., 57, 1305, 10.1211/jpp.57.10.0009 Hirano, 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans, J. Pharmacol. Exp. Ther., 311, 139, 10.1124/jpet.104.068056 Cartiera, 2009, The uptake and intracellular fate of PLGA nanoparticles in epithelial cells, Biomaterials, 30, 2790, 10.1016/j.biomaterials.2009.01.057 Lennernas, 2003, Clinical pharmacokinetics of atorvastatin, Clin. Pharmacokinet., 42, 1141, 10.2165/00003088-200342130-00005 Ishigami, 2001, A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro, Drug Metab. Dispos., 29, 282 Kantola, 1998, Effect of itraconazole on the pharmacokinetics of atorvastatin, Clin. Pharmacol. Ther., 64, 58, 10.1016/S0009-9236(98)90023-6 Kearney, 1993, The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981, Pharm. Res., 10, 1461, 10.1023/A:1018923325359 Jacobsen, 2000, Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin, Drug Metab. Dispos., 28, 1369 Ferreira, 2014, Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke, Inflammation, 37, 1355, 10.1007/s10753-014-9860-y Melo, 2013, Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury, Int. Immunopharmacol., 17, 57, 10.1016/j.intimp.2013.05.016 Pinho-Ribeiro, 2017, Atorvastatin and simvastatin promoted mouse lung repair after cigarette smoke-induced emphysema, Inflammation, 40, 965, 10.1007/s10753-017-0541-5 Schachter, 2005, Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update, Fundam. Clin. Pharmacol., 19, 117, 10.1111/j.1472-8206.2004.00299.x Zeki, 2013, Statin use and asthma control in patients with severe asthma, BMJ Open, 3, 10.1136/bmjopen-2013-003314 Tse, 2014, Statin use in asthmatics on inhaled corticosteroids is associated with decreased risk of emergency department visits, Curr. Med. Res. Opin., 30, 685, 10.1185/03007995.2013.865599 Braganza, 2011, Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial, BMC Pulm. Med., 11, 16, 10.1186/1471-2466-11-16 Ostroukhova, 2009, The effect of statin therapy on allergic patients with asthma, Ann Allergy Asthma Immunol, 103, 463, 10.1016/S1081-1206(10)60261-X Fahimi, 2009, Do statins improve lung function in asthmatic patients? A randomized and double-blind trial, Iran. J. Pharm. Sci., 5, 13 Maneechotesuwan, 2010, Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase, J. Allergy Clin. Immunol., 126, 754, 10.1016/j.jaci.2010.08.005 Hothersall, 2008, Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma, Thorax, 63, 1070, 10.1136/thx.2008.100198 Huang, 2011, Statin use in patients with asthma–a nationwide population-based study, Eur. J. Clin. Investig., 41, 507, 10.1111/j.1365-2362.2010.02434.x Badar, 2014, The effect of atorvastatin on lung function and sputum cell count in chronic asthma patients, IJPR, 4, 194 Lokhandwala, 2012, Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis, BMJ Open, 2, 10.1136/bmjopen-2012-001279 Pagovich, 2010, Statins may improve asthma, J. Allergy Clin. Immunol., 125, AB45, 10.1016/j.jaci.2009.12.210 Cowan, 2010, Simvastatin in the treatment of asthma: lack of steroid-sparing effect, Thorax, 65, 891, 10.1136/thx.2010.138990 Moini, 2012, Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial, Allergy, Asthma Immunol. Res., 4, 290, 10.4168/aair.2012.4.5.290 Olgun Yildizeli, 2017 Criner, 2014, Simvastatin for the prevention of exacerbations in moderate-to-severe COPD, N. Engl. J. Med., 370, 2201, 10.1056/NEJMoa1403086 Lee, 2009, Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension, Clin. Sci., 116, 497, 10.1042/CS20080241 Blamoun, 2008, Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study, Int. J. Clin. Pract., 62, 1373, 10.1111/j.1742-1241.2008.01731.x Lahousse, 2013, Statins, systemic inflammation and risk of death in COPD: the Rotterdam study, Pulm. Pharmacol. Ther., 26, 212, 10.1016/j.pupt.2012.10.008 van Gestel, 2008, Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease, Am. J. Cardiol., 102, 192, 10.1016/j.amjcard.2008.03.038 Rezk, 2013, Anti-inflammatory effects of statin in COPD, Egypt. J. Chest Dis. Tuberc., 62, 65, 10.1016/j.ejcdt.2013.01.006 Bartziokas, 2011, Statins and outcome after hospitalization for COPD exacerbation: a prospective study, Pulm. Pharmacol. Ther., 24, 625, 10.1016/j.pupt.2011.06.003 Neukamm, 2015, Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial, J. Intern. Med., 278, 59, 10.1111/joim.12337 Mroz, 2015, Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study, J. Physiol. Pharmacol., 66, 111 Maneechotesuwan, 2015, Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD, Chest, 148, 1164, 10.1378/chest.14-3138 McAuley, 2014, Simvastatin in the acute respiratory distress syndrome, N. Engl. J. Med., 371, 1695, 10.1056/NEJMoa1403285 Truwit, 2014, Blood institute acute respiratory distress syndrome clinical trials network; rosuvastatin for sepsis-associated acute respiratory distress syndrome, N. Engl. J. Med., 370, 2191, 10.1056/NEJMoa1401520 Dinglas, 2016, One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial, Thorax, 71, 401, 10.1136/thoraxjnl-2015-208017 Kor, 2009, Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury, Intensive Care Med., 35, 1039, 10.1007/s00134-009-1421-8 O'Neal, 2011, Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome, Crit. Care Med., 39, 1343, 10.1097/CCM.0b013e3182120992 Shyamsundar, 2009, Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers, Am. J. Respir. Crit. Care Med., 179, 1107, 10.1164/rccm.200810-1584OC Craig, 2011, A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (the HARP study), Am. J. Respir. Crit. Care Med., 183, 620, 10.1164/rccm.201003-0423OC Wilkins, 2010, Simvastatin as a treatment for pulmonary hypertension trial, Am. J. Respir. Crit. Care Med., 181, 1106, 10.1164/rccm.2009111-699OC Zeng, 2012, Atorvastatin in pulmonary arterial hypertension (APATH) study, Eur. Respir. J., 40, 67, 10.1183/09031936.00149011 Kawut, 2011, Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT, Circulation, 123, 2985, 10.1161/CIRCULATIONAHA.110.015693 Barreto, 2008, Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study, Braz. J. Med. Biol. Res., 41, 657, 10.1590/S0100-879X2008000800003 Liu, 2013, Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease, Exp. Clin. Cardiol., 18, e40 Moosavi, 2013, Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial, Iran Red Crescent Med J, 15, 649, 10.5812/ircmj.8267 Reed, 2011, Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD, COPD, 8, 96, 10.3109/15412555.2011.558545